NCT07137910View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2027

Conditions

Chronic Hepatitis B

Interventions

DRUG

AHB-137

AHB-137 will be injected

Trial Locations (1)

Unknown

AusperBio Investigational Site, Jilin

All Listed Sponsors

lead

Ausper Biopharma Co., Ltd.

INDUSTRY